On December 5, 2022 Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, reported that it will host an investor conference call to provide an update on CPI-818 data that will be presented at the 64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, along with an update on the Company’s development programs (Press release, Corvus Pharmaceuticals, DEC 5, 2022, View Source [SID1234624780]). The conference call and webcast will be held on Monday, December 12 from 4:30 pm – 5:30 pm Eastern Time.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will cover updated results from the Phase 1/1b trial of CPI-818, the Company’s ITK inhibitor, which is being studied for the treatment of immune disorders such as T cell lymphomas, autoimmune and allergic diseases. The investor call will be hosted by Corvus management: Richard A. Miller, M.D., co-founder, president, and chief executive officer, and James T. Rosenbaum, M.D., Senior Vice President of Research.
Details regarding the ASH (Free ASH Whitepaper) poster presentation, which will be available in the poster hall and via the virtual event platform, are as follows:
Date and Time: Monday, December 12, 2022, 6:00 pm CT
Title: ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas
Poster #: 3993
Presenter: Ryan Wilcox, M.D., Ph.D., Section Head, Lymphoma & Myeloma, and Associate Professor, Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan
Conference Call, Webcast and Presentation Slides
The conference call can be accessed by dialing 1- 877-300-8521 (toll-free domestic) or 1- 412-317-6026 (international) and using the conference ID 10172958. The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Corvus website at www.corvuspharma.com. A replay of the webcast will be available for 90 days.